The patent prosecution practice at Boston-based IP-focused firm Wolf, Greenfield & Sacks, P.C., the attorneys of which are highly regarded for their ‘skill, intelligence, expertise and experience’, is headed up by Ed Gates. Its impressive client portfolio includes such names as Pfizer, Sony and Google. Its prosecution work includes advising such clients on all aspects of large-scale patent portfolios and handling protection, management and due diligence as well as FDA-related issues. The team also has well-established post-grant proceedings capabilities and is adept at handling IPRs before the PTAB, which is the area of particular focus of Richard Giunta. This side of the team’s practice was bolstered in July 2023 with the arrival of post-grant expert and ’thought-leader’ Scott McKeown from Ropes & Gray LLP to its newly established Washington DC hub. Patrick Waller heads the biotech practice and is experienced assisting with life sciences-related patent strategy matters as is experienced attorney Hunter Baker. Heather DiPietrantonio specializes in strategic counseling and life cycle management of IP rights relating to life sciences, which is also an area of focus of Oona Johnstone; both are equipped to advise on matters with international scope. All practitioners noted are based in Boston unless stated otherwise.
Testimonials
Collated independently by Legal 500 research team.
‘The skill, intelligence, expertise and experience of the Wolf team is truly amazing. They can provide the highest quality advice on all aspects of IP, licensing, and other related areas, and additionally have an extremely strong litigation and dispute resolution group.'
'They always display the highest degree of integrity and professionalism. They are an incredibly impressive group which has consistently provided exceptional, invaluable services for our mission critical business objectives.’
Key clients
- Bose Corporation
Work highlights
- Handled prosecution of the client's patent portfolio, which includes working with the company as it seeks FDA approval of VP-102.
- Persuaded the PTAB to deny two inter-partes review petitions at the institution stage on patents related to methods of treating facial wrinkles using animal-protein-free botulinum toxin compositions.